BioExpert Network – Experts network to analyse Biotech or Medtech startups

BioExpert Network

Continue reading

Biotechnology Marketing

Biotechnology Marketing

Medtech is a trending topic in the Startup World ! Biotech and Healthcare are booming, and lots of investors trust these subjects as highly potent and valuable. Not for short term investment, of course, but for long term, big profit investments. An important part of being successful or not for this kind of startups is related to Biotechnology Marketing. Will this startup be visible in the Biotech and Lifescience World ?

Some solutions exist enabling medtech startups or biotech companies to find customers for innovative and technical products. For instance, Bio Leads is a new service proposing full list of potential customer depending on customer’s criteria. Define your keywords, geographical restriction, etc… and you will receive a full list of scientists corresponding to your criteria.

More information on Biotech Marketing : BioLeads on Twitter

 

Biotechnology Marketing

Biotechnology Marketing – Biotech Marketing – Lifescience Marketing – Biopharma Marketing – Pharma Marketing – Medtech Marketing – Science Marketing –  Biotechnology Mktg – Biotech Mktg – Lifescience Mktg – Biopharma Mktg – Pharma Mktg – Medtech Mktg – Science Mktg – Marketing Medtech Startups – Marketing Biotech Startups – Marketing Biopharma Startups – Marketing Pharma Startups – Marketing Science Startups

Biotechnology Marketing – Biotech Marketing – Lifescience Marketing – Biopharma Marketing – Pharma Marketing – Medtech Marketing – Science Marketing –  Biotechnology Mktg – Biotech Mktg – Lifescience Mktg – Biopharma Mktg – Pharma Mktg – Medtech Mktg – Science Mktg – Marketing Medtech Startups – Marketing Biotech Startups – Marketing Biopharma Startups – Marketing Pharma Startups – Marketing Science Startups

Biotechnology Marketing – Biotech Marketing – Lifescience Marketing – Biopharma Marketing – Pharma Marketing – Medtech Marketing – Science Marketing –  Biotechnology Mktg – Biotech Mktg – Lifescience Mktg – Biopharma Mktg – Pharma Mktg – Medtech Mktg – Science Mktg – Marketing Medtech Startups – Marketing Biotech Startups – Marketing Biopharma Startups – Marketing Pharma Startups – Marketing Science Startups

 

Startup 365 – Biotech 365 : Marketing Medtech Startup , Biotechnology Marketing , Marketing Biotech Startup , Marketing Biopharma Startup , Marketing Pharma Startup , Marketing Science Startup , Marketing Medtech , Marketing Biotech , Marketing Biopharma , Marketing Pharma , Marketing Science , Biotechnology Marketing , Mktg Medtech , Mktg Biotech , Mktg Biopharma , Mktg Pharma , Mktg Science

Coalesce Product Development – drug delivery devices

//

Coalesce Product Development - drug delivery devices

Another star is twinkling brightly in Cambridge UK’s world-leading galaxy of product design consultancies – providing innovation for global science & technology market leaders.

Coalesce Product Development, headed up by former Sagentia man Dave Ahern, has expanded into significant office and laboratory space at Edinburgh House on the St John’s Innovation Park. The business incubated within St John’s Innovation Centre and has now agreed a five-year lease for space at Edinburgh House totalling 3,796 sq ft in a deal negotiated by Savills.

Cambridge has created a cluster of tech product design consultancies that even the US cannot match. In fact US, Asian and European clients beat a path to Cambridge’s door to turn raw IP into prototypes and marketable products.

Coalesce specialises in drug delivery devices. Engineer Ahern splits his time between working on projects and running the business and has assembled a strong team of engineers. His particular expertise is in respiratory drug delivery devices, built up while working on and managing dry powder inhaler projects for, amongst others, Dey Pharmaceuticals, Chiesi, Novartis and Vectura.

He began his career designing bespoke bomb-disposal robots and then mice and trackballs for high volume manufacture in the Far East. From Logitech, he moved into consultancy with Scientific Generics (now Sagentia) and his focus changed mainly to the medical sector and eventually to drug delivery devices.

Over the past two decades, both as an independent consultant and then at Coalesce Product Development, he has worked on a variety of medical devices, ranging from a gamma knife for Elekta, thoracic surgery equipment for Covedien, an arthroscopic surgical device for Gyrus Medical and a hand-held magnetic probe for sentinel node biopsy procedures for Endomag.

Science Group plc, Sagentia’s parent company, is meanwhile hiring experienced operator Andrew Diston from fellow Cambridge consultancy Medicom Innovation Partner. Diston was also formerly at Cambridge Consultants and has been appointed group science & technology director and a member of the group executive board with effect from September.

He is currently executive VP at Medicom, where he has had global responsibility for the commercial development of the Danish and Cambridge based business. Medicom specialises in designing and developing advanced drug delivery and connected health systems. Prior to Medicom, he spent most of his career at Cambridge Consultants – ultimately as head of the medical technology design and development business.

Science Group comprises four operating businesses, the original and largest being Sagentia, the Cambridge-based science and technology consulting company.

Recent acquisitions by the group have expanded operations into additional vertical markets providing new opportunities for growth. The role of group science & technology director engages the science, engineering and innovation capabilities of the operating businesses to open up new market opportunities.

Science Group has just posted interim results for the six months to the end of June and increased revenue to £17.7 million from £14.1m in the first half of 2015. The adjusted operating profit of £2.5m compared to £2.4m last time. The company reports net cash and freehold property assets of £31.3m, ahead of this stage last year.

Coalesce Product Development – drug delivery devices

• PHOTOGRAPH SHOWS: Edinburgh House on St John’s Innovation Park

Coalesce Product Development – drug delivery devices

Owlstone – cancer breathalyser

//

Owlstone Billy Boyle

Owlstone Medical in Cambridge has closed a $7 million fundraising to commercialise its disease breathalyser.

The business was spun out of parent company, Owlstone Inc, by co-founder Billy Boyle to develop and commercialise the breath test for use in clinical diagnostics and precision medicine with applications in cancer, inflammatory and infectious disease.

The investment round was led by UK-based Medtekwiz Advisory and will be used to fund ongoing clinical trials of the breathalyser in lung and colon cancer screening.

Owlstone Medical was created to leverage proprietary and proven Field Asymmetric Ion Mobility Spectrometry (FAIMS) technology for the advancement of the breath test device.

FAIMS measures volatile organic compound (VOCs) metabolites in patient’s breath or bodily fluids which are specific to disease. Measurement of VOC biomarkers allows diagnosis of disease at a very early stage, to enable more effective treatment and better patient outcomes.

Owlstone Medical is managed by a highly experienced team and supported by world-renowned experts in lung cancer diagnosis. Billy Boyle, the CEO, is an engineering graduate from Cambridge University and one of the original co-founders of Owlstone Inc, which was spun out of the university in 2004 and has raised $28 million in investment and won over $25m in engineering grants – largely from the US Military.

Boyle said: “Securing this funding is further validation of our technology, and we are excited to progress our vision to revolutionise the detection and diagnosis of cancer, infectious and inflammatory diseases.

“The breathalyser we are developing provides clinicians with a highly sensitive, non-invasive diagnostic, which will enable early detection and improve patient outcomes.

“We are also working with pharma partners to develop non-invasive companion diagnostics to better match patients to treatment for emerging personalised therapies.”

Regius Professor Christofer Toumazou, advisor to Medtekwiz and recently appointed to the Owlstone Medical Board, said: “I am delighted to have joined the board and to be involved at such a milestone in the development of the Company.

“With the investment, I look forward to seeing a step change in the way serious disease can be diagnosed and monitored – particularly for colon and lung cancer, which are two of the biggest cancer killers worldwide.”

The potential of the technology to enable rapid detection of disease, without the need for costly, invasive medical procedures, saw Owlstone Medical win the Business Weekly Astra Zeneca-MedImmune Life Science Innovation award. That was mid-March and in the previous month the company won an NHS contract for STRATA, adapting the breathalyser technology for precision medicine and companion diagnostics.

Prior to that, it received a $1.4 million NHS contract for LuCID (Lung Cancer Indicator Detection) to use FAIMS technology in the early detection of lung cancer.

• PHOTOGRAPH SHOWS: Billy Boyle

from Business Weekly http://ift.tt/2947OwZ